From Leo Ehrlich, in response to another question I asked him earlier in the month. You might find it of interest.
Quote:
------------------------------------------------------------------
All good compounds must work via multiple pathways as a cancer drug. Kevetrin acts primarily through regulating p53 activity.
Kevetrin is also HDAC-2 and HDAC-6 regulators, not an HDAC-2 or -6 inhibitor, as is the Crystal Genomics compound, or approved drugs, such as Vorinostat or Romidepsin.
Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. We have also seen that Kevetrin has anti-angiogenic properties.
------------------------------------------------------------------
In Reply to 'duelittle2'
"Bulk" ..Large, diffuse , deep cancers are very difficult to rid the patient of, and in the past and still presently, require a surgical attempt, if not too widespread!
Cancer is fought on a 'Multimodal" level, Instituting as Many therapeutic "Vectors" as possible!
"K" would be Instumental in "Debulking" larger masses w/out the need for invasive Surgery, or even as a "Mop Up" of smaller "nodes" after "Primary" location has been Surgically removed!
Then Once a Cancer is reduced to a certain level, other "Treatment protocals" come in to further reduce/eradicate the Cancer, depending on what is being deal With!
fwiw
News 
Market Data 
Discover 
AI
